Business
STRM.BIO Awarded ARPA-H Contract to Advance Megakaryocyte-Derived Vesicle Platform for In Vivo Cell Engineering and Gene Therapy
STRM.BIO, a start-up biotechnology company pioneering non-viral delivery technologies for in vivo cell and gene therapy, today announced that it has been awarded a contract from the Advanced Research Projects Agency for Health (ARPA-H) through its Engineering of Immune Cells Inside the Body (EMBODY) program. EMBODY is led by ARPA-H Program Manager Daria Fedyukina, Ph.D. The award includes up to $8.4 million in funding to support the first phase of this project, focused on developing and leveragi
About this update from Ginkgo Bioworks Holdings, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., Dec. 3, 2025 /PRNewswire/ -- STRM.BIO, a start-up biotechnology company pioneering non-viral delivery technologies for in vivo cell and gene therapy, today announced that it has been awarded a contract from the Advanced Research Projects Agency for Health (ARPA-H) through its Engineering of Immune Cells Inside the Body (EMBODY) program. EMBODY is led by ARPA-H Program Manager Daria Fedyukina, Ph.D. The award includes up to $8.4 million in funding to support the first phase of this project, focused on developing and leveraging STRM's proprietary megakaryocyte-derived extracellular vesicle (MV) delivery platform for in vivo immune cell engineering.","length":676,"tagName":"p"},{"type":"image","alt":"STRM.BIO logo (PRNewsfoto/STRM.BIO)","displaySize":"","headline":null,"caption":"STRM.BIO logo (PRNewsfoto/STRM.BIO)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":283,"url":"https://media.zenfs.com/en/prnewswire.com/1b582acf6c0ed90f7bd84ae93a56f75d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Z8flgumoB5RSBwBLOJB52A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ5OTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/1b582acf6c0ed90f7bd84ae93a56f75d","width":400,"height":283}},"href":"https://mma.prnewswire.com/media/2295649/STRM_BIO_01_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"STRM.BIO's MV platform represents a novel, cell-derived delivery modality with the potential to overcome many of the key barriers limiting current viral and synthetic in vivo delivery systems.","length":196,"tagName":"p"},{"type":"text","content":""This award marks an important milestone for STRM.BIO in our mission to unlock the potential of extracellular vesicles for in vivo cell and gene therapy," said Michael Luther, Ph.D., CEO of STRM.BIO. "Funding from ARPA-H provides us an extraordinary opportunity to accelerate the development of our MV platform and genetic medicines pipeline to enable precise, efficient, and safe delivery for complex genetic cargos directly to the bone marrow in vivo, with multiple dosing potential when needed."","length":518,"tagName":"p"},{"type":"text","content":"STRM.BIO will act as lead for the project, bringing their novel MV platform and expertise in bone marrow-targeted in vivo delivery. As the Prime Awardee, STRM w...